Find therapies in clinical trials near you – page 26

Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Study Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

Study Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors

Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy